PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thomas Platts-Mills, to Present at GTC’s Allergy Drug Discovery Conference in San Diego, California - Thomas Platts-Mills, to Present ‘The Significance of IgE Antibodies to Galactose-alpha -1, 3-Galactose (alpha-gal)’ at GTC’s Allergy Drug Discovery Conf., San Diego, January 31-February 1
Thomas Platts-Mills, to Present at GTC’s Allergy Drug Discovery Conference in San Diego, California

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2012/11/14 - Thomas Platts-Mills, to Present ‘The Significance of IgE Antibodies to Galactose-alpha -1, 3-Galactose (alpha-gal)’ at GTC’s Allergy Drug Discovery Conf., San Diego, January 31-February 1.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Thomas Platts-Mills, Division Head of Allergy, Asthma & Immunology at the University of Virginia, will be giving a presentation entitled,“The Significance of IgE Antibodies to Galactose-alpha -1, 3-Galactose (alpha-gal)” at GTC’s 2nd Allergy & Respiratory Drug Discovery Conference taking place in San Diego, CA on January 31st – February 1st, 2013.

In 2008, Dr. Platts-Mills’ lab reported that the monoclonal antibody cetuximab (erbitux) was causing anaphylaxis on first infusion because of pre-existing IgE specific for the glycosylation (Chung et al NEJ Med 2008). In addition, they established that the IgE were specific for alpha-gal, which was produced by the mouse cell line. In 2009, they identified a novel form of anaphylaxis to red meat which was also related to IgE specific for alpha-gal (Commins et al JACI 2009). The distribution of IgE specific for alpha-gal in the USA is primarily in the South East, and an important if not the only cause of these antibodies is bites from the lone star tick Amblyommaamericanum (Commins et al JACI 2011). His lab has identified an ecto-parasite induced IgEab response that can create a risk with the use of recombinant molecules made in mammalian cell lines. Alpha-gal on cetuximab is on the FAB portion of the heavy chain, by contrast in some other monoclonals this oligosaccharide is present on the Fc glycosylation site. Together with Dr. Parren, Dr. Platts-Mills has recently reported that this Fc site is not exposed in an intact IgG and is not capable of causing reactions (Nature Biotech, 2011). The specific problem is unlikely to occur again because i) most new MAb don’t have a glycosylation site on the FAB portion and ii) glycosylation on the Fc portion does not create a risk. However, the experience with cetuximab proves a clear warning that post-translational changes in a recombinant molecule can create a target for pre-existing IgE antibodies.

Thomas A. E. Platts-Mills, Ph.D., is the Oscar Swineford Jr. Professor of Medicine and head of the Asthma and Allergic Disease Center at the University of Virginia. Dr. Platts-Mills has carried out research in many different aspects of the role of indoor allergens in asthma.

Dr. Platts-Mills is the former president of the American Academy of Allergy Asthma and Immunology (AAAAI) and has been active in educational efforts nationally for twenty years. He has published over 300 papers and has been a member of the Editorial Board of more than 10 journals. In addition, he was a member of the Immunological Sciences Study Section for the NIH and in 2003, was chairman of the special interest study section on Asthma and Allergic disease for NIAID.

Dr. Platts-Mills has also served on the NAEPP for NHLBI. He has trained more than twenty specialists in Allergic Disease and has supervised eight PhD’s. He received his degree in Animal Physiology from Oxford University (1963) and his MD from St Thomas Hospital. In 1981 he was made a member of the Royal College of Physicians in London and became a fellow in 1982. He did his training in Allergy and Immunology with Dr. Ishizaka and Dr. Lictenstein at John Hopkins (1971-1974) and in 1983 received a PhD in Immunology from London University. He became a member of the Royal Society in 2010.

This conference is also part of the 2nd Novel Immunotherapeutics Summit, which consists of this track and three other tracks:
11th Cytokines & Inflammation
5th Immunotherapeutic & Immunomonitoring
Immunogenicity & Immunotoxicity

Over 200 leading industrial and academic experts will present at this two-day summit. The Novel Immunotherapeutics Summit will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thomas Platts-Mills, to Present at GTC’s Allergy Drug Discovery Conference in San Diego, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)